Sugi Predict

Sugi Predict / Targets / OXER1

OXER1

Oxoeicosanoid receptor 1 · Q8TDS5 · OXER1 on Sugi Atlas →

29,527 patent compounds predicted against OXER1, 19,579 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL286043 SCHEMBL286043 1.00 20/20
SCHEMBL286542 SCHEMBL286542 1.00 20/20
SCHEMBL286543 SCHEMBL286543 1.00 20/20
SCHEMBL286580 SCHEMBL286580 1.00 20/20
SCHEMBL286581 SCHEMBL286581 1.00 20/20
SCHEMBL286689 SCHEMBL286689 1.00 20/20
SCHEMBL286740 SCHEMBL286740 1.00 20/20
SCHEMBL286754 SCHEMBL286754 1.00 20/20
SCHEMBL286802 SCHEMBL286802 1.00 20/20
SCHEMBL286803 SCHEMBL286803 1.00 20/20
SCHEMBL286848 SCHEMBL286848 1.00 20/20
SCHEMBL286860 SCHEMBL286860 1.00 20/20
SCHEMBL286909 SCHEMBL286909 1.00 20/20
SCHEMBL286930 SCHEMBL286930 1.00 20/20
SCHEMBL286937 SCHEMBL286937 1.00 20/20
SCHEMBL286953 SCHEMBL286953 1.00 20/20
SCHEMBL287018 SCHEMBL287018 1.00 20/20
SCHEMBL287124 SCHEMBL287124 1.00 20/20
SCHEMBL287150 SCHEMBL287150 1.00 20/20
SCHEMBL287576 SCHEMBL287576 1.00 20/20

Clinical trials — most relevant to OXER1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial PHASE4NOT_YET_RECRUITING
Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee PHASE4RECRUITING
Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression PHASE4UNKNOWN
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes PHASE3NOT_YET_RECRUITING
Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation PHASE3COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients PHASE2UNKNOWN
Oxytocin for Oxidative Stress and Inflammation PHASE2COMPLETED
Neurosteroids for PTSD in Veterans PHASE2COMPLETED
Oxytocin on Cold Water Task Performance and Recovery PHASE2COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
Endometriosis and Microvascular Dysfunction: Role of Inflammation EARLY_PHASE1RECRUITING
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia nanRECRUITING
Expression of Steroid Receptors in Endometrium nanCOMPLETED
Oxidized LDL With Oxygen Therapy in Acute Coronary Syndrome. nanUNKNOWN
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers nanCOMPLETED
Aromatase Inhibitor Clinical Trial nanUNKNOWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Eicosanoids in Human Heart Failure nanUNKNOWN
Empathy, Psychopathy and Autism: Behavioural Associations and the Role of an Oxytocin Receptor Polymorphism in a Non-clinical Adult Population nanCOMPLETED
Sexual Hormones and Haemostasis: Observations for Women Health nanUNKNOWN
O-LIVE: Impact of a Portuguese Olive Oil in Health Biomarkers nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH nanWITHDRAWN
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation? nanUNKNOWN
Pharmacogenetics of Alcohol: Treatment Implications nanCOMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
Induction of Labor With Oxytocin: When Should Oxytocin be Held? nanCOMPLETED
Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a OXER1 binder may also engage these)

ProteinNameSimilarity
Q8C131 — 0.978 Q8C131 →
Q3ZC80 — 0.976 Q3ZC80 →
FFAR3 Free fatty acid receptor 3 0.975 landscape →
O15529 — 0.975 O15529 →
Q920E0 — 0.975 Q920E0 →
Q149R9 — 0.974 Q149R9 →
LPAR5 Lysophosphatidic acid receptor 5 0.974 landscape →
F8VQN3 — 0.971 F8VQN3 →
P2RY11 P2Y purinoceptor 11 0.971 landscape →
HCAR1 Hydroxycarboxylic acid receptor 1 0.970 landscape →
Q9Z282 — 0.970 Q9Z282 →
O00270 — 0.970 O00270 →
GPR132 Probable G-protein coupled receptor 132 0.969 landscape →
P31392 — 0.969 P31392 →
Q8BYC4 — 0.969 Q8BYC4 →
Q76JU9 — 0.968 Q76JU9 →
Q8BUD0 — 0.968 Q8BUD0 →
GPR17 Uracil nucleotide/cysteinyl leukotriene receptor 0.967 landscape →
Q99678 — 0.966 Q99678 →
P30558 — 0.966 P30558 →
A7YY44 — 0.965 A7YY44 →
P43142 — 0.965 P43142 →
O88634 — 0.965 O88634 →
Q6NS65 — 0.965 Q6NS65 →
Q09QM4 — 0.964 Q09QM4 →
O46685 — 0.964 O46685 →
O09027 — 0.964 O09027 →
O15218 — 0.964 O15218 →
O08707 — 0.963 O08707 →
Q8BFQ3 — 0.963 Q8BFQ3 →